Pemetrexed-associated urticarial vasculitis

Gilberto Lopes, Vladimir Vincek, Luis E. Raez

Research output: Contribution to journalArticle

Abstract

Pemetrexed (Alimta™, Eli Lilly and Company, Indianapolis, IN) is a structurally novel anti-folate agent. The United States Food and Drug Administration has approved pemetrexed for the treatment of patients with malignant pleural mesothelioma and previously treated patients with locally advanced or metastatic non-small cell lung cancer. In the phase III trials that led to its approval, rash was reported in 17 and 22% of patients receiving pemetrexed alone or in combination with cisplatin. However, little has been published about the characteristics of this rash or about its mechanism. In an attempt to contribute to the growing body of knowledge about this new agent, we describe a case in which a patient developed a rash secondary to urticarial vasculitis associated with pemetrexed.

Original languageEnglish (US)
Pages (from-to)247-249
Number of pages3
JournalLung Cancer
Volume51
Issue number2
DOIs
StatePublished - Feb 1 2006

Keywords

  • Non-small cell lung cancer
  • Pemetrexed
  • Rash
  • Skin
  • Urticaria
  • Vasculitis

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Pemetrexed-associated urticarial vasculitis'. Together they form a unique fingerprint.

  • Cite this